Menotropins are prescription fertility medicines used in specialist care. They have established human evidence for defined fertility treatments, but they normally require close medical monitoring.
Still uncertain: The evidence does not support unrelated use or unsupervised use outside specialist fertility care.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Gonadotropin mixture (FSH/LH activity)
Entity type
Gonadotropin biologic mixture
Research focus
Assisted reproduction and fertility
Human evidence
Licensed menotropin medicines have substantial randomized specialist-fertility evidence, including large IVF/ICSI trials and high-responder studies.
Regulatory status
Licensed menotropin products exist, including authorised fertility medicines. An unverified product is not automatically equivalent to a licensed medicine.
Main limitations
Use outside fertility indications or without specialist ovarian/testicular monitoring.
Safety
Major risks include ovarian hyperstimulation syndrome, multifetal gestation, thromboembolic and other reproductive-treatment complications; specialist monitoring is standard.
Evidence reviewed
2026-09-18
i
Licensed menotropin medicines have substantial randomized specialist-fertility evidence, including large IVF/ICSI trials and high-responder studies.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Major risks include ovarian hyperstimulation syndrome, multifetal gestation, thromboembolic and other reproductive-treatment complications; specialist monitoring is standard.
Technical details
Mechanism / biologyProvides follicle-stimulating and luteinising hormone activity to stimulate gonadal function.
Route / formulation boundaryIU potency and biologic-product quality are formulation-specific.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceVerified study/label regimen evidence is available. UK licensed menotrophin dosing example. Open descriptive regimen evidence →
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
2structured study records
2outcome records
7linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
